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Background: S100A12 protein is an endogenous receptor ligand for advanced glycation end products. In this
study, the plasma S100A12 level was assessed as an independent predictor of mortality, and its utility in clinical
settings was examined.
Methods: In a previous cross-sectional study, plasma S100A12 levels were measured in 550 maintenance
hemodialysis patients to determine the association between S100A12 and the prevalence of cardiovascular diseases
(CVD). In this prospective study, the risk of mortality within a two-year period was determined. An integer scoring
system was developed to predict mortality on the basis of the plasma S100A12 levels.
Results: Higher plasma S100A12 levels (≥18.79 ng/mL) were more closely associated with higher all-cause mortality
than lower plasma S100A12 levels (<18.79 ng/mL; P = 0.001). Multivariate Cox proportional hazards analysis revealed
higher plasma S100A12 levels [hazard ratio (HR), 2.267; 95% confidence interval (CI), 1.195–4.302; P = 0.012], age ≥65
years (HR, 1.961; 95%CI, 1.017–3.781; P = 0.044), serum albumin levels <3.5 g/dL (HR, 2.198; 95%CI, 1.218–3.968; P =
0.012), and history of CVD (HR, 2.068; 95%CI, 1.146–3.732; P = 0.016) to be independent predictors of two-year all-
cause mortality. The integer score was derived by assigning points to these factors and determining total scores.
The scoring system revealed trends across increasing scores for predicting the all-cause mortality [c-statistic = 0.730
(0.656–0.804)]. The resulting model demonstrated good discriminative power for distinguishing the validation
population of 303 hemodialysis patients [c-statistic = 0.721 (0.627–0.815)].
Conclusion: The results indicate that plasma S100A12 level is an independent predictor for two-year all-cause
mortality. A simple integer scoring system was therefore established for predicting mortality on the basis of plasma
S100A12 levels.
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In 1960, introduction of the Scribner shunt allowed
identification of continuous hemodialysis [1]. This ad-
vance greatly contributed to prolonged life in patients
with kidney dysfunction. A growing number of patients
throughout the world currently receive maintenance
hemodialysis [2]. For example, in Japan alone, approxi-
mately 290,000 patients are regularly treated with
hemodialysis [3].
Despite these and other successes in the past half cen-
tury, use of dialysis in treatment of end-stage renal dis-
ease (ESRD) is still problematic in certain aspects. First,
the efficiency of dialysis is still limited, and hemodialysis
does not replace all normal kidney functions. Further,
the body of a hemodialysis patient retains several mole-
cules that provoke uremic toxicity, oxidative stress, and
chronic inflammation [4]. Morbidity and mortality rates
among hemodialysis patients consequently remain high
despite considerable technical and scientific improve-
ments in care and treatment of renal disease. The annual
crude mortality rate of dialysis patients in Japan in 2009
was 9.6% according to the Renal Data Registry of the
Japanese Society for Dialysis Therapy [3]. The mean life
expectancy of the dialysis population in Japan was ap-
proximately 40%–60% of that of members of the general
population of the same sex and age [5]. In addition,
aggregate dialysis-associated costs have increased and
have drained national healthcare budgets [2]. Therefore,
each case of hemodialysis must be stratified by the prog-
nostic risk of mortality, and an adjusted therapeutic plan
must be designed for each hemodialysis patient.
The output of the axis of advanced glycation end pro-
ducts (AGE) and their receptor (RAGE) is enhanced in
chronic kidney disease, particularly in ESRD [6,7]. AGE
was originally considered the primary RAGE ligand, but
additional RAGE ligands, including the high-mobility
group box and S100 proteins, have also been identified
[8]. S100A12 was the first member of the S100 family
proven to initiate intracellular signaling by interacting
with RAGE [9,10]. In ESRD patients, mean plasma
S100A12 levels were found to be 2.3-fold higher than
those in control subjects [11,12]. Thus, we hypothesized
that the diagnostic value of plasma S100A12 level as a
predictor of mortality may be superior to that of many
conventional parameters because of its diverse patho-
physiological activities via the AGE–RAGE axis such as
chronic inflammation and tumorigenesis [13,14].
In the present study, the relationship between plasma
S100A12 levels and all-cause mortality was assessed. A
prospective observational study was conducted on patients
undergoing maintenance hemodialysis. A simple prognos-
tic score was developed for maintenance hemodialysis
patients on the basis of their plasma S100A12 levels. Risk




This was a prospective observational cohort study. All
procedures were performed in accordance with the guide-
lines of the Helsinki Declaration on Human Experimenta-
tion and were approved by the Ethics Committees on
Human Research of Kyoto Prefectural University of Medi-
cine, Tojinkai Hospital, Omihachiman Community Me-
dical Center, and Nishijin Hospital. All subjects provided
informed consent. The study was performed in three inde-
pendent dialysis centers in Japan and involved two years
of patient follow-up. Demographic and medical data,
including those on age, sex, smoking history, and comor-
bid conditions such as diabetes, were obtained from me-
dical records.
Subjects
Subjects were 550 hemodialysis patients from two cen-
ters (Tojinkai Hospital and Omihachiman Community
Medical Center). These subjects were described in a pre-
vious cross-sectional study [11] and followed-up as a co-
hort (development population). Another cohort of 303
hemodialysis patients at an additional center (Nishijin
Hospital) was followed-up as external validation popula-
tion. Participants in this external population were en-
rolled in February 2009 according to the same protocol
as that in the development population and observed pro-
spectively until May 2011. All hemodialysis patients
received conventional dialysis for 3–5 h three times per
week with a standard bicarbonate dialysis solution, and
all enrolled patients were clinically stable. None of the
subjects showed clinical evidence of any malignant dis-
ease or overt infection. Basic patient characteristics, rou-
tine laboratory tests, and plasma S100A12 levels were
determined at the beginning of the study. All-cause mor-
tality was the outcome of interest. The date and cause of
death were obtained by reviewing the hospital records.
Cardiovascular mortality was defined as death attribu-
table to myocardial ischemia and infarction, heart fail-
ure, cardiac arrest due to other or unknown causes, or
cerebrovascular injuries [15]. Six patients in the vali-
dation population were excluded from the study because
they moved to another dialysis center or were lost to
follow-up.
Laboratory methods
Blood samples were obtained via vascular access when
dialysis was started on a midweek routine dialysis day.
The plasma was immediately frozen and stored at −80°C
until assay. The levels of urea nitrogen, serum creatinine,
total cholesterol, albumin, hemoglobin, calcium, and
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tory methods. White blood cell and platelet counts were
also determined. The levels of high-sensitivity C-reactive
protein (hs-CRP) were measured using an automatic
analyzer (TBA-120FR; Toshiba, Tokyo, Japan).
Quantitative ELISA for S100A12
A sandwich assay was performed using hCF128 and
hCF113 monoclonal antibodies to quantify plasma
S100A12 levels. S100A12 levels in the samples were
determined by interpolation of absorbance values from a
calibration curve. In our previous study, plasma
S100A12 levels in 42 healthy subjects (29% men; mean
age, 50.5 years) were determined; a median value of 9.4
ng/mL (6.8–12.9) was found [12].
Statistical analyses
Results were expressed as means ± SD. Variables with a
skewed distribution, including plasma S100A12 levels,
were expressed as median and interquartile range (25th–
75th percentiles). Group differences were analyzed using
Student’s t-test, the Mann–Whitney U test, and the χ2
test for normally distributed, non-normally distributed,
and discontinuous variables, respectively. Because our
goal in this study was to arrive at a final prognostic score
that could be easily interpreted and implemented in
practice, all continuous variables were collapsed into the
categorical variables. The normal range of plasma
S100A12 levels in hemodialysis patients has not yet been
standardized [11,16,17]. Therefore, the median value of
the plasma S100A12 levels in the development popula-
tion was used to dichotomize the data. Possible cutoff
points for the other continuous variables for each la-
boratory test were determined according to their clinical
importance using the results of previous studies and
reference values [18-24]. The predictive value of the
plasma S100A12 levels for two-year survival was esti-
mated by the Kaplan–Meier analysis and evaluated using
the log-rank test. The risk factors for all-cause mortality
were first determined using a univariate Cox propor-
tional hazards model, and variables with significant asso-
ciations (P < 0.05) were then included in a multivariate
Cox proportional hazards model in a stepwise proce-
dure. The results of this multivariate analysis were then
used to develop clinical prediction models.
Beta coefficients of variables were further assessed by
the bootstrap method for internal validation and to
reduce bias [25] and then rounded off. The prognostic
risk scores of each individual patient were determined
by assigning points for each factor and determining total
scores. These total risk scores were then stratified into
five categories for all-cause mortality according to the
level of risk. The usefulness of the prediction score was
subsequently evaluated by means of receiver operatingcharacteristic curve analyses and c-statistics [25,26].
After the prediction score had been developed, it was
verified using data from the external validation popula-
tion comprising the 303 ESRD patients receiving
maintenance hemodialysis at an additional independent
center (Nishijin Hospital). All statistical analyses were
performed using SPSS 20.0 for Windows (IBM Japan,
Tokyo, Japan). A P-value <0.05 was considered statisti-
cally significant.
Results
Plasma S100A12 levels and all-cause mortality in the
development population
The development population included 550 ESRD patients
who received maintenance hemodialysis in two indepen-
dent dialysis centers belonging to our affiliated hospitals
(65% men; mean age, 63.4 years; mean duration of
hemodialysis, 9.7 years). Their underlying renal disorders
included diabetic nephropathy (DN; 36.7%) and nonDN
diseases such as chronic glomerulonephritis, hypertensive
nephrosclerosis, polycystic kidney diseases, and others of
unknown etiology (63.3%). A history of cardiovascular dis-
ease (CVD) was noted in 197 patients (35.8%). The me-
dian plasma S100A12 levels in these hemodialysis patients
were 18.79 ng/mL (11.70–30.37). The clinical characteris-
tics of the patients are listed in Table 1. During the median
follow-up of 22.5 months, 50 patients (9%) died. Causes of
death included cardiovascular events (n = 19); infection
(n = 10); malignancy (n = 8); and other causes such as
gastric intestinal bleeding, cachexia and trauma (n = 13).
Significantly higher plasma S100A12 levels were observed
in these patients than in those who survived [25.10 ng/mL
(16.21–47.64) versus 17.93 ng/mL (11.16–29.28); P = 0.001;
Table 1]. The Kaplan–Meier survival curves demonstrated
that higher plasma S100A12 levels (≥18.79 ng/mL) were
associated with higher all-cause mortality than lower
S100A12 levels (<18.79 ng/mL; log-rank test, χ2 = 10.239,
P = 0.001; Figure 1).
The variables associated with all-cause mortality in the
univariate Cox proportional hazards analysis are shown
in Table 2. The following variables were significantly
associated with all-cause mortality: high plasma
S100A12 levels (≥18.79 ng/mL), age (≥65 years), hs-CRP
levels (≥3 mg/L), serum albumin levels (<3.5 g/dL), and
a history of CVD. Further, the multivariate Cox propor-
tional hazards analysis incorporating these factors
showed plasma S100A12 levels ≥18.79 ng/mL [hazard
ratio (HR), 2.267; 95% confidence interval (CI), 1.195–
4.302; P = 0.012] to be an independent predictor of all-
cause mortality (Table 2). Other independent predictors
were age ≥65 years (HR, 1.961; 95%CI, 1.017–3.781;
P = 0.044), serum albumin levels <3.5 g/dL (HR, 2.198;
95%CI, 1.218–3.968; P = 0.012), and a history of CVD
(HR, 2.068; 95%CI, 1.146–3.732; P = 0.016).
Table 1 Clinical characteristics and plasma S100A12 levels in the development population
All (n = 550) Died (n = 50) Survived (n = 500) P valuea
Age (years) 63.4 ± 12.1b 69.9 ± 10.1 62.8 ± 12.1 <0.001**
Male/Female (n) 355/195 32/18 323/177 0.933
Current smoker/nonsmoker (n) 65/485 7/43 58/442 0.616
Duration of HD (years) 9.7 ± 8.4 9.7 ± 8.8 9.7 ± 8.3 0.969
Systolic BP (mmHg) 143.4 ± 26.0 143.4 ± 26.0 142.9 ± 22.0 0.878
Hemoglobin (g/dL) 10.3 ± 1.1 10.4 ± 1.2 10.3 ± 1.1 0.589
White blood cells (/mm3) 5729 ± 1816 5814 ± 1554 5720 ± 1841 0.728
Platelet (104/μL) 16.8 ± 5.9 16.1 ± 6.0 16.8 ± 5.9 0.398
hs-CRP (mg/L) 1.0 (0.4–3.0)c 2.1 (0.8–6.3) 0.9 (0.4–2.7) <0.001**
Creatinine (mg/dL) 10.5 ± 2.6 9.6 ± 2.8 10.6 ± 2.6 0.010*
Albumin (g/dL) 3.7 ± 0.4 3.5 ± 0.4 3.7 ± 0.4 <0.001**
Sodium (mEq/L) 139.5 ± 3.0 138.4 ± 3.0 139.6 ± 2.9 0.003**
Potassium (mEq/L) 4.6 ± 0.7 4.4 ± 0.8 4.6 ± 0.7 0.175
Adjusted calcium (mg/dL) 9.3 ± 0.6 9.2 ± 0.6 9.3 ± 0.6 0.380
Phosphate (mg/dL) 4.7 ± 1.1 4.5 ± 1.2 4.7 ± 1.1 0.283
Calcium (mg/dL) × Phosphate (mg/dL) 41.5 ± 10.5 39.0 ± 10.4 41.8 ± 10.5 0.074
Total cholesterol (mg/dL) 162.3 ± 45.8 158.4 ± 43.2 162.7 ± 46.1 0.534
DN/nonDN (n) 202/348 22/28 180/320 0.263
History of CVD/no history of CVD (n) 197/353 30/20 167/333 <0.001**
Plasma S100A12 levels (ng/mL) 18.79 (11.70–30.37)c 25.10 (16.21–47.64) 17.93 (11.16–29.28) 0.001**
a Died versus survived. bMeans ± SD (all such values). cMedian value; 25%–75% value shown in parentheses (all such values). HD = hemodialysis, BP = blood
pressure, hs-CRP = high-sensitivity C-reactive protein, DN = diabetic nephropathy, CVD = cardiovascular disease.
*P < 0.05, **P < 0.01.
Figure 1 Kaplan–Meier estimates of two-year survival by
baseline plasma S100A12 levels. The median value of plasma
S100A12 levels of all participants at baseline were 18.79 ng/mL. The
participants were divided into a lower S100A12 group (solid line)
and a higher S100A12 group (dotted line) according to this median
value (χ2 = 10.239, P = 0.001 by the log-rank test).
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Beta coefficients of the independent variables obtained
by multivariate Cox proportional hazards analysis were
assessed using 1000 bootstrap resamples. No significant
difference between original beta and bootstrapped coeffi-
cients was observed (age, 0.674 vs. 0.713; albumin, 0.788
vs. 0.780; history of CVD, 0.727 vs. 0.730; plasma
S100A12 levels, 0.919 vs. 0.935). One point (rounded
off ) was assigned to each of the four independent
predictors of all-cause mortality (Table 3). The integer
score obtained by assigning and totaling the points for
each factor ranged from 0 to 4. All-cause mortality in
hemodialysis patients by risk score assignment is
depicted in Figure 2, with trends shown across increa-
sing scores for predicting all-cause mortality. The two-
year c-statistic of the development model was 0.730
(0.656–0.804).
On the basis of the results for all-cause mortality as
stratified by risk score, the 550 patients in the develop-
ment population were further categorized into three
groups as follows: low risk (n = 267; 48.5%), moderate
risk (n = 254; 46.2%), and high risk (n = 29; 5.3%), corre-
sponding to risk scores of ≤1, 2–3, and 4, respectively
(Figure 3).
Table 2 Results of Cox’s proportional hazards analysis of clinical parameters and all-cause mortality











Age ≥65 years 0.972 2.643 1.425–
4.900
0.002** 0.674 1.961 1.017–
3.781
0.044*
Male −0.003 0.997 0.560–
1.776
0.992
Current smoker 0.190 1.210 0.544–
2.689
0.648
Duration of HD ≥10 years −0.068 0.934 0.520–
1.677
0.819
Systolic BP <110 mmHg 0.721 2.057 0.759–
5.575
0.156
110–140 mmHg - - - -
≥140 mmHg 0.158 1.171 0.641–
2.140
1.171
Hemoglobin <10 g/dL 0.006 1.006 0.554–
1.826
0.984
10–11 g/dL - - - -
≥11 g/dL 0.569 1.767 0.681–
4.589
0.242
White blood cells ≥10000/mm3 −0.112 0.894 0.123–
6.472
0.911
Platelet ≥35 × 104/μL 0.330 0.719 0.175–
2.959
0.648
hs-CRP ≥3 mg/L 0.957 2.604 1.490–
4.552
0.001**
Albumin <3.5 g/dL 1.016 2.761 1.580–
4.828
<0.001** 0.788 2.198 1.218–
3.968
0.012*
Potassium ≥5.5 mEq/L 0.128 1.136 0.484–
2.667
0.769
Phosphate ≥6 mg/dL −0.211 0.810 0.322–
2.041
0.655
Total Cholesterol ≥200 mg/dL 0.123 1.130 0.508–
2.513
0.764
DN 0.300 1.349 0.772–
2.359
0.293
History of CVD 1.045 2.844 1.615–
5.009
<0.001** 0.727 2.068 1.146–
3.732
0.016*




0.002** 0.919 2.267 1.195–
4.302
0.012*
HD = hemodialysis, BP = blood pressure, hs-CRP = high-sensitivity C-reactive protein, DN = diabetic nephropathy, CVD = cardiovascular disease,
HR = hazard ratio, 95%CI = 95% confidence interval.
**P < 0.01, *P < 0.05.
Table 3 Integer risk score
Predictor variable Risk score value
Age ≥65 years 1
Albumin <3.5 g/dL 1
History of CVD 1
Plasma S100A12 levels≥ 18.79ng/mL 1
Total risk score ×/4
CVD = cardiovascular disease.
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The validation population included 303 ESRD patients
in whom maintenance hemodialysis was performed in
another affiliated hospital. The clinical characteristics of
these patients are listed in Table 4. In this validation
population, the two-year all-cause mortality was 10.9%
(n = 33). Causes of death included cardiovascular events
(n = 18); infection (n = 9); malignancy (n = 4); and other
causes such as cirrhosis and cachexia (n = 2). The values
for the all-cause mortality in the validation population
Figure 2 Development of the risk score. Increasing risk of the
two-year all-cause mortality with increasing risk score is evident. n = total
number of patients in each score.
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each of the three risk groups (Figure 3). The developed
model demonstrated good discriminative power in the
validation population [c-statistic = 0.721 (0.627–0.815)].
Discussion
This study followed-up 550 patients on maintenance
hemodialysis after measurement of their plasma S100A12
levels. The main findings of the present study are as
follows. A higher plasma S100A12 level (≥18.79 ng/mL) in
hemodialysis patients was a significant predictor of the
two-year all-cause mortality. In addition to the plasma
S100A12 levels, age ≥65 years, serum albumin levels
<3.5 g/dL, and a history of CVD were independent predic-
tors of the two-year all-cause mortality. The predicting
integer score developed using these four factors provided
statistically significant information. Finally, external valid-
ation in a cohort of 303 hemodialysis patients at an inde-
pendent center demonstrated that the simple integer scoreFigure 3 External validation of the risk score. The risk score
derived from the development population also predicted the two-
year all-cause mortality in the validation population. Solid bars =
development population; open bar = validation population.proposed here provided good discriminative power, and
therefore serves as a useful predictive model of mortality
in hemodialysis patients.
Prolonged subclinical inflammation causes release of
intracellular molecules that alert the immune system to
danger. Recent studies reported that these endogenous
damage-associated molecular pattern (DAMP) molecules
or alarmins, which are released from necrotic cells and
activated leucocytes, play a crucial role in the inflamma-
tory response [27]. Examples of putative DAMPs include
endogenous RAGE ligands such as high-mobility group
box 1 and S100 proteins (S100A8/A9 and S100A12),
interleukins (IL) such as IL-1α, heat-shock proteins, and
nucleosome [27]. The S100A12 expression is high in
inflammatory diseases such as rheumatoid arthritis,
Crohn’s disease, Kawasaki disease, and atherosclerosis
[28-31]. Atherosclerosis, which causes CVD, is also
characterized by the presence of subclinical chronic
inflammation [32]. Furthermore, abnormal persistence
of DAMPs in chronic inflammation and in tumor micro-
environments is associated with carcinogenesis [14].
Signals that activate RAGE, which is also regarded as
a prototypic DAMP receptor, may trigger a positive
regulatory loop that maintains the inflammatory micro-
environment required for the promotion of tumor deve-
lopment [13]. Thus, the interaction of S100A12 with
RAGE may be involved in diverse processes such as
inflammatory-induced atherosclerosis, defense against
infection, and tumorigenesis. These factors contribute to
the all-cause mortality in hemodialysis patients; thus,
measurement of S100A12 levels may provide a sensitive
discriminative predictor.
Two observational studies have been conducted exa-
mining the relationship between mortality and S100A12
in hemodialysis patients. Nakashima et al. [16] per-
formed an ad hoc analysis of 184 prevalent hemodialysis
patients in Sweden. They showed that the S100A12 level
was an independent predictor of the all-cause and CVD-
related mortality. Adjustment for plasma IL-6 levels as
an inflammatory marker significantly attenuated the
association with the all-cause mortality but not with
respect to cardiovascular mortality. Because plasma IL-6
levels were not measured in this larger prospective
study, a direct comparison with the results of the
Swedish study was not possible. The low mortality rate
in the current study (9%) did not allow statistical evalu-
ation of the function of each cause of death, probably
because of differences in the circumstances between
dialysis facilities. Very recently, a prospective study of
261 Czech hemodialysis patients by Kalousova et al.
[17] found a relationship between S100A12 levels and
infection-related mortality. In contrast to the present
study and the Swedish study, they found no difference
between baseline S100A12 levels in the hemodialysis
Table 4 Clinical characteristics and plasma S100A12 levels in the validation population
All (n = 303) Died (n = 33)a Survived (n = 264)a P valueb
Age (years) 69.4 ± 11.7c 74.9 ± 10.5 68.7 ± 11.4 0.003**
Male/Female (n) 195/108 27/6 165/99 0.029*
Current smoker/nonsmoker (n) 51/252 5/28 46/218 0.744
Duration of HD (years) 7.4 ± 7.2 6.6 ± 4.4 7.6 ± 7.5 0.254
Systolic BP (mmHg) 148.3 ± 23.0 146.2 ± 26.7 148.5 ± 22.6 0.594
Hemoglobin (g/dL) 10.4 ± 1.2 9.9 ± 1.4 10.5 ± 1.2 0.007**
White blood cells (/mm3) 5438 ± 1579 5867 ± 1707 5393 ± 1557 0.104
Platelet (104/μL) 17.7 ± 5.8 16.8 ± 5.8 17.7 ± 5.8 0.380
hs-CRP (mg/L) 0.9 (0.4–3.4) d 1.4 (0.6–7.8) 0.9 (0.4–3.0) 0.013*
Creatinine (mg/dL) 9.0 ± 2.8 7.4 ± 2.6 9.3 ± 2.7 <0.001**
Albumin (g/dL) 3.6 ± 0.4 3.3 ± 0.5 3.6 ± 0.3 <0.001**
Sodium (mEq/L) 139.6 ± 2.8 138.8 ± 3.5 139.7 ± 2.6 0.172
Potassium (mEq/L) 4.9 ± 0.8 4.7 ± 0.8 4.9 ± 0.8 0.076
Adjusted calcium (mg/dL) 9.1 ± 0.7 9.2 ± 0.6 9.1 ± 0.7 0.404
Phosphate (mg/dL) 4.9 ± 1.2 4.6 ± 1.4 5.0 ± 1.2 0.162
Calcium (mg/dL) × Phosphate (mg/dL) 42.7 ± 11.5 39.5 ± 11.9 43.3 ± 11.5 0.078
Total cholesterol (mg/dL) 146.6 ± 34.3 142.6 ± 42.9 147.3 ± 32.7 0.453
DN/nonDN (n) 132/171 21/12 110/154 0.017*
History of CVD/no history of CVD (n) 86/217 15/18 69/195 0.020*
Plasma S100A12 levels (ng/mL) 20.39 (12.65–37.98)d 28.60 (14.18–43.80) 19.45 (12.54–35.46) 0.035*
aSix patients were excluded from the final evaluation because they moved to another dialysis center or were lost to follow-up. bDied versus survived. cMeans ± SD
(all such values). dMedian value; 25%–75% value shown in parentheses (all such values). HD = hemodialysis, BP = blood pressure, hs-CRP = high-sensitivity C-
reactive protein, DN = diabetic nephropathy, CVD = cardiovascular disease.
*P < 0.05, **P < 0.01.
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stitial nephritis and polycystic kidney disease were
present in 26.8% and 14.6% of patients in that study, re-
spectively; these values differed significantly from those
in our subjects. Therefore, direct comparison between
their study results and those of the current study was
difficult. However, the relationship between mortality
due to infection and S100A12 should be considered.
The risk scoring system developed in this study, which
included the plasma S100A12 levels, was useful in pre-
dicting the two-year all-cause mortality. A score of 0–4
was calculated using data for age, albumin levels, history
of CVD, and S100A12 levels derived from analysis of
550 participants. This score successfully predicted
mortality even in the validation population. Further-
more, this simple model, which requires no extensive
computation, can be used in clinical settings for rapid
evaluation of the patient status. Considering the risk
stratification and planning involved in the management
of hemodialysis patients, this score system may provide
useful and meaningful information to practitioners. Be-
cause the population of hemodialysis patients is increasing
and because of economic and medical staff limitations,
intensive treatment of all the patients who receivedmaintenance hemodialysis is not possible [33,34]. For
hemodialysis patients at high risk according to our pro-
posed scoring system, a strong intention to treat, such as
more careful observation of patient status; and shorter
intervals between imaging studies to screen for CVD, ma-
lignancy, and infectious disease are recommended. In this
context, the proposed scoring system may be a useful risk
stratification tool in clinical settings. Prospective verifica-
tion of the clinical usefulness of this system in our
affiliated clinics is planned in future.
Some limitations of the present study must be acknow-
ledged. First, prevalent but not incident dialysis patients
were selected for inclusion. Second, although the sample
size analyzed here was larger than that in previous studies
performed in Sweden and Czech Republic [16,17] on the
relationship between S100A12 levels and mortality in
hemodialysis patients, the total number of deaths in this
Japanese study was small. However, one report suggested
that clinical prognosis is better in Japanese hemodialysis
patients compared with those in other countries [35].
Third, other possible risk factors for mortality in ESRD
patients, such as vascular calcification, nutritional state,
subjective comorbid score, levels of candidate markers
(brain natriuretic peptide, fetuin-A, and IL-6), dialysis
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http://www.biomedcentral.com/1471-2369/14/16adequacy, and residual renal function may be important,
but were not measured here. Finally, the diagnostic assays
currently used for measurement of S100A12 levels are
useful for research purposes only. To date, no commer-
cially available routine tests have become available for
determining S100A12 levels in clinical studies. In addition,
normal and reference plasma values are still under debate.Conclusion
In conclusion, in the present study of 550 maintenance
hemodialysis patients, the plasma S100A12 level was veri-
fied as an independent predictor of two-year mortality.
The simple integer score was shown to be successful in
predicting mortality using four significant variables, includ-
ing plasma S100A12 levels. In addition to studies verifying
the usefulness of the proposed scoring system, interven-
tional studies involving S100A12 are further planned to
clarify the relationship between plasma S100A12 levels and
hemodialysis mortality.
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